Colorectal cancer (metastatic) - aflibercept: notice of appeal

Aflibercept in combination with irinotecan and fluorouracil-based therapy for the treatment of metastatic colorectal cancer which has progressed following prior oxaliplatin-based therapy [ID514] : Notice of Appeal

NICE has received one appeal against the Final Appraisal Determination on the above technology from the following organisation:

  • Sanofi

The appeal panel will convene on Thursday 23 January 2014 at RIBA, 66 Portland Place, London W1B 1AD to hear oral representations from the appellants. 

Members of the public, including consultees and commentators for this appraisal, and the press, may request to attend the hearing. The number of places for observers is constrained by the venue, and priority will be given to members of the public who are not employed by the appellant. There are twenty five places available for this appeal hearing. 

Where possible, requests to attend should be made using the form that will be available on the Institute's website. This form will be available from  28 November 2013 only. The website registration will allow requests to attend to be granted on a first-come, first-served basis. The registration period for this appeal will end at 5pm on 12 December 2013. Further details relating to public attendance at this appeal are available on the same webpage as above.

A limited number of places at the appeal hearing will be reseved for members of the public who do not have access to the internet. These places should be applied for in writing, addressed to the Appeals Coordinator at NICE, to arrive before 5pm on 12 December 2013. Written requests to attend will also be granted on a first-come, first-served basis.

This page was last updated: 27 November 2013